In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Nevro nets $146mm in public convertible notes financing

Executive Summary

Nevro Corp. (devices to treat chronic pain) netted $145.5mm through the public offering of $150mm aggregate principal amount of 1.75% convertible senior notes due 2021. (The company had initially proposed an offering of $125mm aggregate principal amount.) The notes convert to 10.3770 shares of common stock per $1k principal (equivalent to $96.37/share; the stock was averaging $69.16). Nevro will use about $21mm of the proceeds to fully repay its term loan with Capital Royalty Partners. Additional proceeds will go toward ongoing US commercialization efforts for its Senza implantable spinal cord stimulator, which received PMA a year ago for indications in chronic intractable pain of the trunk and limbs.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Implantable Devices
Deal Status
  • Final
Deal Type
  • Financing
    • Convertible Debt
    • FOPO

Related Companies